# Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP

> **NCT02049866** · PHASE2 · COMPLETED · sponsor: **Elizabeth Shane** · enrollment: 33 (actual)

## Conditions studied

- Adult Idiopathic Generalized Osteoporosis

## Interventions

- **DRUG:** Denosumab

## Key facts

- **NCT ID:** NCT02049866
- **Lead sponsor:** Elizabeth Shane
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-19
- **Primary completion:** 2020-03-31
- **Final completion:** 2021-12-23
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2022-12-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02049866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02049866, "Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02049866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*